NCT07583953 — Suzhou Abogen Biosciences neoantigen vaccine trial
An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors
Registry record
| Registry ID | NCT07583953 ↗ |
|---|---|
| Lead sponsor | Suzhou Abogen Biosciences Co., Ltd. |
| Collaborators | The First Affiliated Hospital of Soochow University |
| Phase | Phase EARLY_PHASE1 |
| Status | Not Yet Recruiting |
| Indication | Solid Tumors |
| Enrollment | 50 participants (target) |
| Start date | 2026-04-17 |
| Primary completion | 2029-01-31 (est.) |
| Last registry update | 13 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07583953), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
FAQ
What phase is NCT07583953?
NCT07583953 (An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors) is registered on ClinicalTrials.gov as Phase EARLY_PHASE1, sponsored by Suzhou Abogen Biosciences Co., Ltd..
Is NCT07583953 recruiting?
As of the 2026-05-13 registry update, NCT07583953 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07583953?
The lead sponsor is Suzhou Abogen Biosciences Co., Ltd.. Collaborators: The First Affiliated Hospital of Soochow University.
What condition does NCT07583953 study?
The registered condition is Solid Tumors. Primary completion is listed as 2029-01-31 (estimated).
Are results available for NCT07583953?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07583953.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.